Cargando…
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
BACKGROUND: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression un...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912535/ https://www.ncbi.nlm.nih.gov/pubmed/36765293 http://dx.doi.org/10.1186/s12885-023-10609-8 |
| _version_ | 1784885227203592192 |
|---|---|
| author | Karacin, Cengiz Oksuzoglu, Berna Demirci, Ayşe Keskinkılıç, Merve Baytemür, Naziyet Köse Yılmaz, Funda Selvi, Oğuzhan Erdem, Dilek Avşar, Esin Paksoy, Nail Demir, Necla Göksu, Sema Sezgin Türker, Sema Bayram, Ertuğrul Çelebi, Abdüssamet Yılmaz, Hatice Kuzu, Ömer Faruk Kahraman, Seda Gökmen, İvo Sakin, Abdullah Alkan, Ali Nayır, Erdinç Uğraklı, Muzaffer Acar, Ömer Ertürk, İsmail Demir, Hacer Aslan, Ferit Sönmez, Özlem Korkmaz, Taner Celayir, Özde Melisa Karadağ, İbrahim Kayıkçıoğlu, Erkan Şakalar, Teoman Öktem, İlker Nihat Eren, Tülay Urul, Enes Mocan, Eda Eylemer Kalkan, Ziya Yıldırım, Nilgün Ergün, Yakup Akagündüz, Baran Karakaya, Serdar Kut, Engin Teker, Fatih Demirel, Burçin Çakan Karaboyun, Kubilay Almuradova, Elvina Ünal, Olçun Ümit Oyman, Abdilkerim Işık, Deniz Okutur, Kerem Öztosun, Buğra Gülbağcı, Burcu Belen Kalender, Mehmet Emin Şahin, Elif Seyyar, Mustafa Özdemir, Özlem Selçukbiricik, Fatih Kanıtez, Metin Dede, İsa Gümüş, Mahmut Gökmen, Erhan Yaren, Arzu Menekşe, Serkan Ebinç, Senar Aksoy, Sercan İmamoğlu, Gökşen İnanç Altınbaş, Mustafa Çetin, Bülent Uluç, Başak Oyan Er, Özlem Karadurmuş, Nuri Erdoğan, Atike Pınar Artaç, Mehmet Tanrıverdi, Özgür Çiçin, İrfan Şendur, Mehmet Ali Nahit Oktay, Esin Bayoğlu, İbrahim Vedat Paydaş, Semra Aydıner, Adnan Salim, Derya Kıvrak Geredeli, Çağlayan Yavuzşen, Tuğba Doğan, Mutlu Hacıbekiroğlu, İlhan |
| author_facet | Karacin, Cengiz Oksuzoglu, Berna Demirci, Ayşe Keskinkılıç, Merve Baytemür, Naziyet Köse Yılmaz, Funda Selvi, Oğuzhan Erdem, Dilek Avşar, Esin Paksoy, Nail Demir, Necla Göksu, Sema Sezgin Türker, Sema Bayram, Ertuğrul Çelebi, Abdüssamet Yılmaz, Hatice Kuzu, Ömer Faruk Kahraman, Seda Gökmen, İvo Sakin, Abdullah Alkan, Ali Nayır, Erdinç Uğraklı, Muzaffer Acar, Ömer Ertürk, İsmail Demir, Hacer Aslan, Ferit Sönmez, Özlem Korkmaz, Taner Celayir, Özde Melisa Karadağ, İbrahim Kayıkçıoğlu, Erkan Şakalar, Teoman Öktem, İlker Nihat Eren, Tülay Urul, Enes Mocan, Eda Eylemer Kalkan, Ziya Yıldırım, Nilgün Ergün, Yakup Akagündüz, Baran Karakaya, Serdar Kut, Engin Teker, Fatih Demirel, Burçin Çakan Karaboyun, Kubilay Almuradova, Elvina Ünal, Olçun Ümit Oyman, Abdilkerim Işık, Deniz Okutur, Kerem Öztosun, Buğra Gülbağcı, Burcu Belen Kalender, Mehmet Emin Şahin, Elif Seyyar, Mustafa Özdemir, Özlem Selçukbiricik, Fatih Kanıtez, Metin Dede, İsa Gümüş, Mahmut Gökmen, Erhan Yaren, Arzu Menekşe, Serkan Ebinç, Senar Aksoy, Sercan İmamoğlu, Gökşen İnanç Altınbaş, Mustafa Çetin, Bülent Uluç, Başak Oyan Er, Özlem Karadurmuş, Nuri Erdoğan, Atike Pınar Artaç, Mehmet Tanrıverdi, Özgür Çiçin, İrfan Şendur, Mehmet Ali Nahit Oktay, Esin Bayoğlu, İbrahim Vedat Paydaş, Semra Aydıner, Adnan Salim, Derya Kıvrak Geredeli, Çağlayan Yavuzşen, Tuğba Doğan, Mutlu Hacıbekiroğlu, İlhan |
| author_sort | Karacin, Cengiz |
| collection | PubMed |
| description | BACKGROUND: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). METHODS: A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. RESULTS: The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. CONCLUSION: Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10609-8. |
| format | Online Article Text |
| id | pubmed-9912535 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99125352023-02-11 Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy Karacin, Cengiz Oksuzoglu, Berna Demirci, Ayşe Keskinkılıç, Merve Baytemür, Naziyet Köse Yılmaz, Funda Selvi, Oğuzhan Erdem, Dilek Avşar, Esin Paksoy, Nail Demir, Necla Göksu, Sema Sezgin Türker, Sema Bayram, Ertuğrul Çelebi, Abdüssamet Yılmaz, Hatice Kuzu, Ömer Faruk Kahraman, Seda Gökmen, İvo Sakin, Abdullah Alkan, Ali Nayır, Erdinç Uğraklı, Muzaffer Acar, Ömer Ertürk, İsmail Demir, Hacer Aslan, Ferit Sönmez, Özlem Korkmaz, Taner Celayir, Özde Melisa Karadağ, İbrahim Kayıkçıoğlu, Erkan Şakalar, Teoman Öktem, İlker Nihat Eren, Tülay Urul, Enes Mocan, Eda Eylemer Kalkan, Ziya Yıldırım, Nilgün Ergün, Yakup Akagündüz, Baran Karakaya, Serdar Kut, Engin Teker, Fatih Demirel, Burçin Çakan Karaboyun, Kubilay Almuradova, Elvina Ünal, Olçun Ümit Oyman, Abdilkerim Işık, Deniz Okutur, Kerem Öztosun, Buğra Gülbağcı, Burcu Belen Kalender, Mehmet Emin Şahin, Elif Seyyar, Mustafa Özdemir, Özlem Selçukbiricik, Fatih Kanıtez, Metin Dede, İsa Gümüş, Mahmut Gökmen, Erhan Yaren, Arzu Menekşe, Serkan Ebinç, Senar Aksoy, Sercan İmamoğlu, Gökşen İnanç Altınbaş, Mustafa Çetin, Bülent Uluç, Başak Oyan Er, Özlem Karadurmuş, Nuri Erdoğan, Atike Pınar Artaç, Mehmet Tanrıverdi, Özgür Çiçin, İrfan Şendur, Mehmet Ali Nahit Oktay, Esin Bayoğlu, İbrahim Vedat Paydaş, Semra Aydıner, Adnan Salim, Derya Kıvrak Geredeli, Çağlayan Yavuzşen, Tuğba Doğan, Mutlu Hacıbekiroğlu, İlhan BMC Cancer Research BACKGROUND: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). METHODS: A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. RESULTS: The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. CONCLUSION: Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10609-8. BioMed Central 2023-02-10 /pmc/articles/PMC9912535/ /pubmed/36765293 http://dx.doi.org/10.1186/s12885-023-10609-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Research Karacin, Cengiz Oksuzoglu, Berna Demirci, Ayşe Keskinkılıç, Merve Baytemür, Naziyet Köse Yılmaz, Funda Selvi, Oğuzhan Erdem, Dilek Avşar, Esin Paksoy, Nail Demir, Necla Göksu, Sema Sezgin Türker, Sema Bayram, Ertuğrul Çelebi, Abdüssamet Yılmaz, Hatice Kuzu, Ömer Faruk Kahraman, Seda Gökmen, İvo Sakin, Abdullah Alkan, Ali Nayır, Erdinç Uğraklı, Muzaffer Acar, Ömer Ertürk, İsmail Demir, Hacer Aslan, Ferit Sönmez, Özlem Korkmaz, Taner Celayir, Özde Melisa Karadağ, İbrahim Kayıkçıoğlu, Erkan Şakalar, Teoman Öktem, İlker Nihat Eren, Tülay Urul, Enes Mocan, Eda Eylemer Kalkan, Ziya Yıldırım, Nilgün Ergün, Yakup Akagündüz, Baran Karakaya, Serdar Kut, Engin Teker, Fatih Demirel, Burçin Çakan Karaboyun, Kubilay Almuradova, Elvina Ünal, Olçun Ümit Oyman, Abdilkerim Işık, Deniz Okutur, Kerem Öztosun, Buğra Gülbağcı, Burcu Belen Kalender, Mehmet Emin Şahin, Elif Seyyar, Mustafa Özdemir, Özlem Selçukbiricik, Fatih Kanıtez, Metin Dede, İsa Gümüş, Mahmut Gökmen, Erhan Yaren, Arzu Menekşe, Serkan Ebinç, Senar Aksoy, Sercan İmamoğlu, Gökşen İnanç Altınbaş, Mustafa Çetin, Bülent Uluç, Başak Oyan Er, Özlem Karadurmuş, Nuri Erdoğan, Atike Pınar Artaç, Mehmet Tanrıverdi, Özgür Çiçin, İrfan Şendur, Mehmet Ali Nahit Oktay, Esin Bayoğlu, İbrahim Vedat Paydaş, Semra Aydıner, Adnan Salim, Derya Kıvrak Geredeli, Çağlayan Yavuzşen, Tuğba Doğan, Mutlu Hacıbekiroğlu, İlhan Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy |
| title | Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy |
| title_full | Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy |
| title_fullStr | Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy |
| title_full_unstemmed | Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy |
| title_short | Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy |
| title_sort | efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under cdk 4/6 inhibitor therapy |
| topic | Research |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912535/ https://www.ncbi.nlm.nih.gov/pubmed/36765293 http://dx.doi.org/10.1186/s12885-023-10609-8 |
| work_keys_str_mv | AT karacincengiz efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT oksuzogluberna efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT demirciayse efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT keskinkılıcmerve efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT baytemurnaziyetkose efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT yılmazfunda efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT selvioguzhan efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT erdemdilek efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT avsaresin efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT paksoynail efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT demirnecla efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT goksusemasezgin efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT turkersema efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT bayramertugrul efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT celebiabdussamet efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT yılmazhatice efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT kuzuomerfaruk efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT kahramanseda efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT gokmenivo efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT sakinabdullah efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT alkanali efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT nayırerdinc efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT ugraklımuzaffer efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT acaromer efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT erturkismail efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT demirhacer efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT aslanferit efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT sonmezozlem efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT korkmaztaner efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT celayirozdemelisa efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT karadagibrahim efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT kayıkcıogluerkan efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT sakalarteoman efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT oktemilkernihat efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT erentulay efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT urulenes efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT mocanedaeylemer efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT kalkanziya efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT yıldırımnilgun efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT ergunyakup efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT akagunduzbaran efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT karakayaserdar efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT kutengin efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT tekerfatih efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT demirelburcincakan efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT karaboyunkubilay efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT almuradovaelvina efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT unalolcunumit efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT oymanabdilkerim efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT isıkdeniz efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT okuturkerem efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT oztosunbugra efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT gulbagcıburcubelen efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT kalendermehmetemin efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT sahinelif efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT seyyarmustafa efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT ozdemirozlem efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT selcukbiricikfatih efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT kanıtezmetin efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT dedeisa efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT gumusmahmut efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT gokmenerhan efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT yarenarzu efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT menekseserkan efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT ebincsenar efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT aksoysercan efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT imamoglugokseninanc efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT altınbasmustafa efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT cetinbulent efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT ulucbasakoyan efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT erozlem efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT karadurmusnuri efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT erdoganatikepınar efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT artacmehmet efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT tanrıverdiozgur efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT cicinirfan efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT sendurmehmetalinahit efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT oktayesin efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT bayogluibrahimvedat efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT paydassemra efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT aydıneradnan efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT salimderyakıvrak efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT geredelicaglayan efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT yavuzsentugba efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT doganmutlu efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy AT hacıbekirogluilhan efficacyofsubsequenttreatmentsinpatientswithhormonepositiveadvancedbreastcancerwhohaddiseaseprogressionundercdk46inhibitortherapy |